Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00162513 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | — | Hadassah Medical OrganizationOTHER | 1 | Apr 28, 2011 | clinicaltrials |
| NCT01141673 | Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia | unknown | — | 100 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00101647 | Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia | completed | Phase 2 | 197 | Bristol-Myers SquibbINDUSTRY | 23 | Apr 15, 2011 | clinicaltrials |
| NCT00101595 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Bristol-Myers SquibbINDUSTRY | 20 | Apr 14, 2011 | clinicaltrials |
| NCT00337454 | Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | completed | Phase 1 / Phase 2 | 48 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00531310 | Reduced Intensity AlloSCT in(CML) With Persistent Disease(CML) | terminated | Phase 2 | 5 | Columbia UniversityOTHER | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00226512 | To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning | withdrawn | Phase 3 | 203 | Hadassah Medical OrganizationOTHER | 1 | Apr 8, 2011 | clinicaltrials |
| NCT00186966 | Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 3 | 394 | Dutch Childhood Oncology GroupOTHER | 1 | Apr 6, 2011 | clinicaltrials |
| NCT01329471 | Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML) | unknown | — | 75 | Hillel Yaffe Medical CenterOTHER_GOV | 1 | Apr 6, 2011 | clinicaltrials |
| NCT00400673 | A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia | completed | Phase 2 | 581 | Northern Italy Leukemia GroupOTHER | 1 | Apr 1, 2011 | clinicaltrials |
| NCT01114087 | Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility(GLIFERTI) | completed | N/A | 2 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 29, 2011 | clinicaltrials |
| NCT01315925 | Pre-hospital Risk Factors for Invasive Fungal Infection(SEIFEM 2010) | unknown | — | 1,000 | Catholic University of the Sacred HeartOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00136422 | Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | completed | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00136448 | High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00136461 | A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT01034410 | A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 90 | Antisoma ResearchINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT01066494 | A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 20 | Antisoma ResearchINDUSTRY | 2 | Jan 17, 2011 | clinicaltrials |
| NCT01054937 | Single Dose Study With 4SC-203 in Healthy Volunteers | completed | Phase 1 | 60 | 4SC AGINDUSTRY | 1 | Jan 13, 2011 | clinicaltrials |
| NCT00486265 | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 47 | AstraZenecaINDUSTRY | 2 | Dec 21, 2010 | clinicaltrials |
| NCT00482703 | A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia | completed | Phase 1 / Phase 2 | 23 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 17, 2010 | clinicaltrials |
| NCT01030718 | Rollover Study of BMS-354825 in Patients With CML and Ph+ALL | completed | Phase 1 / Phase 2 | 54 | Bristol-Myers SquibbINDUSTRY | 0 | Dec 14, 2010 | clinicaltrials |
| NCT00497991 | Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 65 | AstraZenecaINDUSTRY | 4 | Dec 8, 2010 | clinicaltrials |
| NCT01247493 | Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)(m-FLAI) | completed | Phase 2 | 108 | Seoul National University HospitalOTHER | 1 | Nov 24, 2010 | clinicaltrials |
| NCT00689000 | Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 57 | Chroma TherapeuticsINDUSTRY | 1 | Oct 22, 2010 | clinicaltrials |
| NCT01019161 | An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 5 | AstraZenecaINDUSTRY | 1 | Oct 20, 2010 | clinicaltrials |
| NCT01220544 | Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells | unknown | Phase 1 / Phase 2 | 30 | Charite University, Berlin, GermanyOTHER | 1 | Oct 14, 2010 | clinicaltrials |
| NCT00715637 | Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study | unknown | Phase 3 | 420 | Antisoma ResearchINDUSTRY | 23 | Oct 13, 2010 | clinicaltrials |
| NCT01195506 | Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML) | unknown | — | 40 | Taipei Medical University WanFang HospitalOTHER | 1 | Oct 6, 2010 | clinicaltrials |
| NCT00382954 | Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML | completed | Phase 1 | 55 | University of KentuckyOTHER | 1 | Sep 29, 2010 | clinicaltrials |
| NCT01133886 | Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure(DEC-MDS) | unknown | Phase 2 | 50 | King's College LondonOTHER | 1 | Sep 3, 2010 | clinicaltrials |
| NCT00101816 | Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate | completed | Phase 2 | 124 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 10, 2010 | clinicaltrials |
| NCT00103844 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 32 | Aug 10, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00279773 | Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 | 34 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 30, 2010 | clinicaltrials |
| NCT01146977 | Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)(CBF(+)AML) | unknown | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 22, 2010 | clinicaltrials |
| NCT01145846 | Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)(AIvsAD) | unknown | Phase 3 | 316 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 17, 2010 | clinicaltrials |
| NCT01142375 | Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells | unknown | — | 100 | Taipei Medical University WanFang HospitalOTHER | 0 | Jun 11, 2010 | clinicaltrials |
| NCT00048503 | Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older | completed | Phase 2 | 88 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Apr 27, 2010 | clinicaltrials |
| NCT00390715 | Treatment of Acute Myeloblastic Leukemia in Younger Patients | completed | — | 600 | PETHEMA FoundationOTHER | 1 | Mar 15, 2010 | clinicaltrials |
| NCT00322673 | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 14 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00834002 | Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission(CCRG 05-001) | completed | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Feb 9, 2010 | clinicaltrials |
| NCT01063660 | Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 75 | medac GmbHINDUSTRY | 1 | Feb 5, 2010 | clinicaltrials |
| NCT00464217 | Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 5, 2010 | clinicaltrials |
| NCT01039363 | Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia | unknown | Phase 2 | 27 | Samsung Medical CenterOTHER | 1 | Dec 25, 2009 | clinicaltrials |
| NCT01034839 | High-dose Cytarabine and Survival in AML | completed | — | 499 | University of Sao Paulo General HospitalOTHER | 1 | Dec 18, 2009 | clinicaltrials |
| NCT01020175 | Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation | completed | Phase 3 | 350 | European Society for Blood and Marrow TransplantationNETWORK | 1 | Nov 25, 2009 | clinicaltrials |
| NCT00081926 | Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 4 | 112 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT01015196 | Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation(AML2001) | completed | Phase 2 / Phase 3 | 832 | Nantes University HospitalOTHER | 1 | Nov 18, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2011source: clinicaltrials